• In recent weeks, Medtronic reported fourth-quarter fiscal 2026 results with revenue growth, an adjusted earnings per share beat, a higher dividend, and new fiscal 2027 guidance, while also expanding its commercial partnership with Retia Medical to distribute the Argos Cardiac Output Monitor into high-risk surgical and critical care settings, including Europe.
• At the same time, Medtronic’s containment of a prior cyberattack without impact on patient safety or core operations, combined with its broader push into advanced hemodynamic monitoring, highlights how the company is working to reinforce operational resilience while deepening its presence in complex cardiac care.
• We’ll now examine how Medtronic’s expanded Retia partnership and stronger quarterly results may influence its existing investment narrative.

Outshine the giants: these 16 early-stage AI stocks could fund your retirement.

Medtronic Investment Narrative Recap

To own Medtronic, you have to believe its diversified device portfolio and steady innovation can offset near term pressure from underperforming segments and product mix on margins. Right now, the key upside catalyst is execution on new cardiac and diabetes technologies, while the biggest risk is that heavy R&D and commercial spending fails to translate into sufficient adoption and margin improvement. The recent cyberattack and Retia expansion do not materially change that risk reward balance in the short term.

Among the latest updates, the expanded partnership with Retia Medical to distribute the Argos Cardiac Output Monitor is most relevant. It aligns directly with Medtronic’s push into higher value, data rich cardiac and critical care tools that could support mix over time. If these kinds of advanced monitoring platforms scale as part of Medtronic’s broader cardiovascular ecosystem, they may help reinforce the company’s core growth and margin catalysts.

Yet despite these positives, investors should also be aware that...

Medtronic’s narrative projects $41.5 billion revenue and $6.6 billion earnings by 2029. This requires 4.5% yearly revenue growth and about a $1.8 billion earnings increase from $4.8 billion today.

Uncover how Medtronic's forecasts yield a $98.00 fair value, a 18% upside to its current price.

Exploring Other Perspectives

Some of the most pessimistic analysts were assuming only about 2 percent annual revenue growth to roughly US$38.6 billion and earnings of about US$6.2 billion by 2029, so this new Retia and cyber update could either soften or reinforce those lower expectations depending on how you think it affects adoption, margins and overall execution risk.

Explore 7 other fair value estimates on Medtronic - why the stock might be worth just $87.06!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Medtronic research is our analysis highlighting 5 key rewards that could impact your investment decision.
• Our free Medtronic research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Medtronic's overall financial health at a glance.

Want Some Alternatives?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 31 best rare earth metal stocks of the very few that mine this essential strategic resource.
• The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.